Menopur (Menotrophin)

Menotrophin provides both follicle‑stimulating hormone (FSH) and luteinising hormone (LH) activity. FSH binds to receptors on granulosa cells, promoting cell proliferation and estradiol production, while LH activates receptors on theca cells, stimulating androgen synthesis that is converted to estrogen. The combined effect supports follicle growth, maturation and ovulation.

The dose of Menopur is individualized; a prescribing physician determines the amount and schedule based on the patient’s ovarian response, treatment protocol, and clinical monitoring. Dosage adjustments are made according to ultrasound findings and hormone levels, and the regimen may vary between cycles.

Menopur is intended for use before conception to induce ovulation; its safety in established pregnancy has not been established, and it is generally not recommended during pregnancy. Limited data exist for breastfeeding, and the product should be used only if the potential benefit justifies any possible risk to the infant.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and the necessary import documentation.

Menopur contains both FSH and LH activity in a single preparation, whereas some alternatives provide only FSH (e.g., follitropin alfa) or separate LH preparations. This combined profile can simplify dosing for protocols that require both hormones, but the choice of product depends on individual patient response, protocol design and physician preference.

Menopur must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Vials should remain in the original packaging until use, and any unused portion should be discarded according to local regulations after the recommended storage period.

Menopur is supplied as an injectable solution for intramuscular or subcutaneous injection. The medication is reconstituted with the appropriate diluent, drawn into a sterile syringe, and administered according to the prescribing clinician’s instructions, typically in a clinical setting or under supervised self‑administration.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can range from mild to severe and may cause abdominal pain, fluid accumulation, thrombosis or renal impairment, as well as the possibility of multiple pregnancy and rare allergic reactions such as anaphylaxis. Close monitoring during treatment is essential.

Menopur is contraindicated in women with uncontrolled thyroid disease, ovarian cysts, active hormone‑dependent tumors, severe ovarian hyperstimulation syndrome, or known hypersensitivity to menotrophin or any excipients. It should also be avoided in individuals for whom ovarian stimulation is not indicated.